Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

Discover the latest advancements in BPDCN treatment, including targeted therapies and promising chemotherapy regimens for ...

A treatment that is effective against hearing loss caused by the 'MPZL2 gene' mutation has been developed. A research team ...

Thoracic medical oncologists and early drug development specialists at Memorial Sloan Kettering Cancer Center (MSK) continue to investigate new ways to improve outcomes for this patient population.

Each type of cancer is unique, and there’s no one-size-fits-all treatment. Immunotherapy and targeted medications allow doctors to treat cancer using different approaches that help improve overall ...

Multiple myeloma (MM) is a genetically complex and heterogenous malignancy with a 5-year survival rate of approximately 60%. Patients experience periods of relapse and remission, with prognosis ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...